Outcomes in COVID-19 vidofludimus calcium studies

0 0.5 1 1.5+ All studies 0% 1 220 Improvement, Studies, Patients Relative Risk Mortality 0% 1 220 Ventilation 0% 1 220 RCTs 0% 1 220 Late 0% 1 220 Vidofludimus Calcium for COVID-19 c19early.org November 2025 Favorsvidofludimus calcium Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Vehresch.. (DB RCT) 0% 1.00 [0.14-6.97] death 2/110 2/110 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.14-6.97] 2/110 2/110 no change All studies 0% 1.00 [0.14-6.97] 2/110 2/110 no change 1 vidofludimus calcium COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors vidofludimus calcium Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Vehresch.. (DB RCT) 0% 1.00 [0.14-6.97] 2/110 2/110 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.14-6.97] 2/110 2/110 no change All studies 0% 1.00 [0.14-6.97] 2/110 2/110 no change 1 vidofludimus calcium COVID-19 mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Favors vidofludimus calcium Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Vehresch.. (DB RCT) 0% 1.00 [0.33-3.01] 6/110 6/110 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.33-3.01] 6/110 6/110 no change All studies 0% 1.00 [0.33-3.01] 6/110 6/110 no change 1 vidofludimus calcium COVID-19 mechanical ventilation result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Favors vidofludimus calcium Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Vehresch.. (DB RCT) 0% 1.00 [0.14-6.97] death 2/110 2/110 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.14-6.97] 2/110 2/110 no change All studies 0% 1.00 [0.14-6.97] 2/110 2/110 no change 1 vidofludimus calcium COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors vidofludimus calcium Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Vehresch.. (DB RCT) 0% 1.00 [0.14-6.97] death 2/110 2/110 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.14-6.97] 2/110 2/110 no change All studies 0% 1.00 [0.14-6.97] 2/110 2/110 no change 1 vidofludimus calcium COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors vidofludimus calcium Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Vehresch.. (DB RCT) 0% 1.00 [0.14-6.97] 2/110 2/110 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.14-6.97] 2/110 2/110 no change All studies 0% 1.00 [0.14-6.97] 2/110 2/110 no change 1 vidofludimus calcium COVID-19 RCT mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Favors vidofludimus calcium Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Vehresch.. (DB RCT) 0% 1.00 [0.14-6.97] death 2/110 2/110 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.14-6.97] 2/110 2/110 no change All studies 0% 1.00 [0.14-6.97] 2/110 2/110 no change 1 vidofludimus calcium COVID-19 peer reviewed studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors vidofludimus calcium Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Vehresch.. (DB RCT) 0% 1.00 [0.14-6.97] death 2/110 2/110 Improvement, RR [CI] Treatment Control Vehresch.. (DB RCT) 0% 1.00 [0.33-3.01] ventilation 6/110 6/110 Vehresch.. (DB RCT) 0% 1.00 [0.36-2.76] progression 7/110 7/110 Vidofludimus calcium COVID-19 outcomes c19early.org November 2025 Favors vidofludimus calcium Favors control